Aptevo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Preclinical Data for Trispecific Antibody APVO451 in Solid Tumors
Aptevo Therapeutics Inc. has announced the first presentation of preclinical data for its new trispecific antibody candidate, APVO451. The data were presented at the Society for Immunotherapy of Cancer $(SITC)$ Annual Meeting on November 8, 2025. APVO451 is designed to address immune suppression in the tumor microenvironment of hard-to-treat solid tumors, including urothelial, breast, and pancreatic cancers. The molecule targets nectin-4 on tumor cells and incorporates Aptevo's proprietary CRIS-7-derived CD3 binding domain to activate T cells, as well as engaging CD40 to restore the function of antigen-presenting cells. The company reported that APVO451 is advancing through ongoing preclinical studies with the goal of supporting future clinical development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1099359) on November 10, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。